No Data
Lingrui Pharmaceutical's Capsule Up for Selection for China's Centralized Traditional Chinese Drug Procurement
Henan Lingrui Pharmaceutical (600285.SH): The company's products are planned to be selected for the national Chinese Patent Medicine procurement alliance's centralized bulk procurement.
On January 2, Gelonghui reported that Henan Lingrui Pharmaceutical (600285.SH) announced its participation in the tendering work for the national Chinese Patent Medicine procurement alliance's centralized bulk purchasing. According to the proposed selection results for the national Chinese Patent Medicine procurement alliance's centralized bulk purchasing (ZCYLM-2024-1) published by the Hubei Medical Insurance Service Platform on December 30, 2024, the company's product, Qiqi Jiangtang capsules, is slated for selection in this centralized bulk purchasing for Chinese Patent Medicine.
Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Henan Lingrui Pharmaceutical (600285.SH) granted 1.25 million restricted Stocks at a grant price of 10.96 yuan per share.
Henan Lingrui Pharmaceutical (600285.SH) announced that the company will hold the ninth Director meeting on December 19, 2024...
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
Are Robust Financials Driving The Recent Rally In Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Stock?
